WO2002012185A1 - Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols - Google Patents

Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols Download PDF

Info

Publication number
WO2002012185A1
WO2002012185A1 PCT/KR2001/001362 KR0101362W WO0212185A1 WO 2002012185 A1 WO2002012185 A1 WO 2002012185A1 KR 0101362 W KR0101362 W KR 0101362W WO 0212185 A1 WO0212185 A1 WO 0212185A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
compound
process according
aziridine
Prior art date
Application number
PCT/KR2001/001362
Other languages
French (fr)
Inventor
Won Koo Lee
Seong-Ho Shin
Hyun-Joon Ha
Original Assignee
Chembionex Co., Ltd.
Hansol Chemience Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chembionex Co., Ltd., Hansol Chemience Co., Ltd. filed Critical Chembionex Co., Ltd.
Priority to AU2001277801A priority Critical patent/AU2001277801A1/en
Publication of WO2002012185A1 publication Critical patent/WO2002012185A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • C07C247/10Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00Compounds containing azido groups
    • C07C247/02Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/08Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms

Definitions

  • the obtained optically pure 2,3-diaminopropanol is used to produce, for example, hydroxymethylpiperazine which is useful as an intermediate of medicament.
  • the processes for producing an optically active piperazine was proposed via a catalytic hydrogenation (U.S. Patent No. 5,977,364), or resolution of racemic mixture (U.S. Patent No. 5,945,534) were known.
  • the present invention is characterized by a process for preparing 2,3- diaminopropanol from a chiral diamine.
  • morpholine is used as amine in the present process, D-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol etc. can be produced, which is biologically active. Disclosure of the Invention
  • the present invention provides a process for producing 2,3-diaminopropanol in high yields of more than 90% by ring opening an inactivated optically pure aziridine and reacting it with various amines.
  • the obtained 2,3-diaminopropanol is used in the synthesis of high value-added compounds, such as hydroxymethylpiperazine, D-threo-l-phenyl-2- decanoylamino-3 -morpholino- 1 -propanol, etc.
  • the object of the present invention is to provide a process for producing 2,3- diaminopropanol derivatives of formula (2) which act as intermediates in the synthesis of medicaments from aziridine alcohol of formula (1) and a process for producing the other useful compounds therefrom. Accordingly, the processes of the present invention can have four preparations as follows.
  • a compound of formula (1) was reacted with halotrialkylsilane [Si(R) 3 X] to carry out a regiospecific ring opening reaction of the aziridine, and then the resulting intermediate was reacted with an amine (NHR 3 R 4 ) to produce a compound of formula (2).
  • This can be schematically illustrated in the following Scheme 1
  • R 1 is selected from the group consisting of hydrogen; alkyl; cycloalkyl; 3- triazinyl or pyrimidyl acyl; aryl; hydrocarbon residues; aralkyl; and those substituted with suitable substituent(s), and includes 4-chlorophenyl, 4-methoxyphenyl, benzyl, 2,4- dimethoxyphenyl, (lR)-phenylethyl and (lS)-phenylethyl, preferences are given to (1R)- phenylethyl and (lS)-phenylethyl;
  • R 2 is selected from the group consisting of hydrogen; alkyl including, but not limiting to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-
  • Preparation 2 may be applied.
  • aryl includes, but is not limited to, C 5 -C 14 aromatic hydrocarbon group such as phenyl, indenyl, naphthyl, phenanthrenyl, anthracenyl etc.
  • heteroaryl includes, but is not limited to, 1 to 4 unsaturated 3- to 8- membered heterocyclic moieties containing 1 to 4 nitrogen atoms (e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl etc.); saturated 3- to 8-membered heterocyclic moieties containing 1 to 4 nitrogen atom(s) (e.g., pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl etc.); unsaturated condensed heterocyclic moieties containing 1 to 4 nitrogen atom(s) (e.g., indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl,
  • pyrrolyl pyrazolyl
  • imidazolyl oxazolyl
  • isoxazolyl isoxazolyl
  • thiazolyl isothiazolyl
  • 1,2,3 -oxadiazolyl triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, morpholinyl.
  • suitable substituent(s) includes, but is not limited to, lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1-, 2- or 3-butenyI, 1-, 2-, 3- or 4-pentenyl etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargon
  • haIotrialkylsilane[Si(R) 3 X] includes, but is not limited to, chlorotrimethylsilane, bromotrimethylsilane, iodotriethylsilane.
  • lower means that the number of carbon is 1 to 6.
  • lower alkyl indicates, but not limited to C,-C 6 linear or branched moiety(ies) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, 1,1-dimethylbutyl, 2,2- dimethylbutyl, and the term "alkyl” includes, but is not limited to, linear or branched C,-C 20 alkyl such as methyl, ethyl, propyl, 2-ethylhexyl, octyl, dodecyl, hexadecyl, and octadecyl.
  • all the preparation processes of the present invention are usually carried out in a solvent such as acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or other solvents which do not adversely influence the reaction.
  • a solvent such as acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or other solvents which do not adversely influence the reaction.
  • a conventional organic solvent can be used. More preferably halogenated organic solvent, and most preferably methylene chloride can be used.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • An azidoaminoalcohol of formula (3) was produced by reacting a compound of formula (1), the same starting material as in Preparation 1 by a known process (Y. Lim, Tetrahedron Letters, 1995, 36, 8431, and B. C. Kim, Tetrahedron, 1996, 52, 12117), reacting the compound with azidotrialkylsilane[Si(R') 3 N 3 ] to carry out a regiospecific ring opening reaction of the aziridine.
  • 2,3-diaminopropanol of formula (4) was produced by reducing the obtained compound of formula (3) using a conventional azido reduction process. According to this procedure, a product wherein R 3 and R 4 are both hydrogen [i.e., a compound of formula (4)] can be produced.
  • Aldotrialkylsilane[Si(R') 3 N 3 ] M as used herein includes, but is not limited to, azidotrimethylsilane or azidotriethylsilane. Preference is given to azidotrimethylsilane.
  • the "reduction” according to this invention can be commonly carried out by the conventional procedures in the art such as chemical reduction and catalytic reduction. The following is a brief introduction of the reduction procedure, which can be used in the present invention.
  • Suitable reducing agents to be used in the chemical reduction are hydride (e.g., lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride etc.); mixture of borane and tetrahydrofuran or di(lower)alkyl sulfide (e.g., dimethyl sulfide etc.); or mixture of metal (e.g., tin, zinc, iron etc.) or acid compound (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid etc.).
  • hydride e.g., lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride etc.
  • borane and tetrahydrofuran or di(lower)alkyl sulfide e.g., dimethyl sulfide etc.
  • metal e.g., tin,
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire etc.), palladium catalyst (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate etc.), nickel catalyst (e.g., reduced nickel, nickel oxide, Raney nickel etc.), cobalt catalyst (e.g., reduced cobalt, Raney cobalt etc.), iron catalyst (e.g., reduced iron, Raney iron, Ullmann iron etc.) and the like.
  • platinum catalyst e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire etc.
  • palladium catalyst e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palla
  • the known reduction procedures can be utilized in reducing an azido group to an amino group in Preparation 2, and the typical examples are reduction by LiAlH 4 , reduction by Ph 3 P and catalytic reduction (catalytic hydrogenation), etc.
  • the reduction is usually carried out in a solvent such as water, alcohol, tetrahydrofuran, dioxane, N,N-dimethylformamide, or a mixture thereof; or other solvents which do not adversely influence the reaction.
  • a solvent such as water, alcohol, tetrahydrofuran, dioxane, N,N-dimethylformamide, or a mixture thereof; or other solvents which do not adversely influence the reaction.
  • the acid used in chemical reduction is liquid, it can also act as a solvent.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
  • a compound of formula (6) can be produced by subjecting 2,3-diaminopropanol of formula (5) (i.e., the compound of formula (2) obtained from Preparation 1, wherein R 3 is hydrogen) to reduction as shown in Scheme 3, preferably reduction using a compound having a dialdehyde group and a hydride reducing agent.
  • the compound of formula (6) was subjected to a conventional reduction in the presence of a compound capable of producing an amino protecting group (i.e., amino protector), preferably reduction by catalytic hydrogenation (catalytic reduction) as described above to produce a compound of formula (7).
  • Typical compound of formula (7) includes l,4-di-t-Boc-2(R)-hydroxymethylpiperazine (wherein "Boc” stands for tert-butyloxycarbonyl).
  • R 1 , R 2 and R 4 are as defined hereinbefore, and R 5 is an amino protecting group, which is suitable for protecting (or blocking) an amino group from chemical reaction, and is easily removable after completing the desired reaction on the other site.
  • Typical examples of this type include substituted or unsubstituted acyl, aryl, aralkoxymethyl or aralkyl group etc.
  • the name or size of amino protecting groups is not critical because they are removed after completing the desired reaction. However, those having 1 to 20 carbon atom(s), particularly 1 to 8 carbon atom(s) can be preferably used.
  • acyl group as used herein can have the broadest meaning in regard to this process. It includes an acyl group derived from aliphatic, aromatic aliphatic, aromatic or heterocyclic carboxylic acid or sulfonic acid as well as alkoxycarbonyl, aryloxycarbonyl, particularly aralkoxycarbonyl group.
  • acyl group include, but are not limited to, alkanoyl such as acetyl, propionyl, butyryl, decanoyl etc.; aralkanoyl such as phenylacetyl etc.; aroyl such as benzoyl or toluyl etc.; aryloxyalkanoyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, Boc, 2-iodoethoxycarbonyl etc.; aralkylcarbonyl such as Cbz(carbobenzoxy), 4-methoxybenzyloxycarbonyl, Fmoc (9- fluorenylmethoxycarbonyl) etc.; arylsulfonyl.
  • alkanoyl such as acetyl, propionyl, butyryl, decanoyl etc.
  • aralkanoyl such as phenylacety
  • amino protecting group the preference is given to Boc, and also to Cbz, Fmoc, benzyl or acetyl.
  • amino protector t-butyl carbonate, methylcarbamate, ethylcarbamate or 9- fluorenylmethylcarbamate can be preferably used.
  • the “hydride” includes, but is not limited to, lithium aluminum hydride, sodium borohydride or sodium cyanoborohydride.
  • a compound having a dialdehyde group is well known in the art, and preferably glyoxal can be used.
  • the compound of formula (8) can be prepared by subjecting R 1 group of the compound of formula (2) to a conventional reduction procedure, preferably to a reduction using catalytic hydrogenation as described hereinbefore, and then reacting it with alkanoyl halide (R 6 X).
  • alkanoyl halide R 6 X
  • Typical examples of the compound of formula (8) include D-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol.
  • R 1 , R 2 , R 3 and R 4 and the redction are as defined hereinbefore,
  • R 6 includes, but is not limited to, alkanoyl group such as acetyl, propionyl, butyryl, valeryl, pivaloyl, hexanoyl, isobutyryl, 2-ethylbutyryl, 3,3-dimethylbutyryl, decanoyl, preference is given to decanoyl, and X is fluoro, chloro, bromo or iodo.
  • alkanoyl group such as acetyl, propionyl, butyryl, valeryl, pivaloyl, hexanoyl, isobutyryl, 2-ethylbutyryl, 3,3-dimethylbutyryl, decanoyl, preference is given to decanoyl
  • X is fluoro, chloro, bromo or iodo.
  • N-[(S)-l-phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol (201 mg) was dissolved in methylene chloride, to which azidotrimethylsilane (0.25 ml) was added.
  • the reaction mixture was stirred at ambient temperature for 12 hours, was treated with IN of aqueous hydrochloric acid solution and then was stirred for 1 more hour.
  • the solution was neutralized with sodium hydrogen carbonate, and the reaction product was extracted twice each with 5.0 mi of methylene chloride.
  • the combined organic extracts were dried under anhydrous magnesium sulfate, and the solution was filtered, concentrated in vacuo and purified to give 154 mg of product as an oil.
  • N-[(S)-l-phenylethyl]aziridine-2(R)-methanol 60 mg was dissolved in 1.0 ml of acetonitrile, and then 107 mg of sodium iodide and 86 mg of chlorotnmethylsilane were added to this solution. After stirring the reaction mixture at ambient temperature for 1 hour and 50 minutes, 16.8 mg of pyrrolidine was added, and then the reaction mixture was heated for 2 hours with stirring. After the reaction was completed, the reaction mixture was treated with 1.2N aqueous hydrochloric acid solution, neutralized with sodium hydrogen carbonate and extracted twice each with 5 mi of methylene chloride. The combined organic extracts were rinsed with brine, and dried under anhydrous magnesium sulfate. The solution was filtered, concentrated in vacuo, and purified to give 73 mg of titled product as an oil.
  • the present invention produces the known 2,3-diaminopropanol in high yields of more than 90% by ring opening an inactivated optically pure aziridine and reacting with various amines.
  • the obtained 2,3-diaminopropanol can be used in synthesis of high value-added fine chemical compounds, such as hydroxymethylpiperazine, D-threo-l-phenyl-2-decanoylamino- 3 -morpholino-1 -propanol etc.

Abstract

The invention relates to a process for producing 2,3-diaminopropanol of formula (II) from aziridine of formula (I) wherein, R1 is selected from a group consisting of hydrogen, alkyl, cycloalkyl, acyl, aryl, hydrocarbon residues, aralkyl, and those groups substituted with suitable substituent(s); R2 is selected from a group consisting of hydrogen, alkyl, cycloalkyl, C¿2?-C5-alkenyl, aralkyl which may be optionally substituted with suitable substituent(s), aryl which may be optionally substituted with suitable substituent(s), and heteroaryl which may be optionally substituted with suitable substituent(s); each of R?3 and R4¿ is independently selected from a group consisting of hydrogen, C¿1?-C12 alkyl, C1-C12 alkylcarbonyl, C1-C12 alkyloxycarbonyl, aryl, mono- or di(C1-C12)alkylamino, mono- or di(C1-C12)amino carbonyl, wherein C1-C12 may be optionally substituted, or R?3 and R4¿, together with nitrogen atom which they are attached to, may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C¿1?-C12)alkylamino C1-C4 alkylidene.

Description

PROCESS FOR PREPARING 2,3-DIAMINOPROPANOLS AND SYNTHESIS OF OTHER COMPOUNDS USING 2,3-DIAMINOPROPANOLS
Technical Field 2,3-diaminopropanol is an important material used in production of fine chemicals, particularly medicaments or their intermediates or other catalyst and high value-added compounds (D. Lucet, Angew. Chem. Int. Ed. Engl. 1998, 37, 2580-2627). Background Art
Heretofore, the processes for preparing 2,3-diaminopropanol by directly incorporating two amines into alkene, or oxidizing the alkene, and subsequently subjecting to animation (A. Chong, J Am. Chem. Soc. 1977, 99, 3420, and H. C. Kolb, Chem. Rev. 1994, 94, 2483-2547) were known. However, the present invention relates to a process for preparing 2,3-diaminopropanol by regiospecifϊc ring opening of an optically pure aziridine ring using nitrogen nucleophile. Of course, researches have been made as to the method of preparing azide by ring opening an aziridine having no protecting groups on the nitrogen atom, or an activated aziridine ring having a strong electron-withdrawing group such as tosyl on the nitrogen atom (G. Swift, J. Org. Chem. 1967, 32, 511-517 and T. Turoki, Chem. Lett. 1995, 337-338). But, these processes have limitations that the reaction yield is very low, e.g., not more than 40% and only an activated aziridine should be used. Also, these processes have low regioselectivity. Thus, the present inventors propose a process for producing 2,3- diaminopropanol, by ring opening an optically pure aziridine, and reacting it with an amine.
The obtained optically pure 2,3-diaminopropanol is used to produce, for example, hydroxymethylpiperazine which is useful as an intermediate of medicament. The processes for producing an optically active piperazine was proposed via a catalytic hydrogenation (U.S. Patent No. 5,977,364), or resolution of racemic mixture (U.S. Patent No. 5,945,534) were known. The present invention is characterized by a process for preparing 2,3- diaminopropanol from a chiral diamine. In addition, when morpholine is used as amine in the present process, D-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol etc. can be produced, which is biologically active. Disclosure of the Invention
The present invention provides a process for producing 2,3-diaminopropanol in high yields of more than 90% by ring opening an inactivated optically pure aziridine and reacting it with various amines. The obtained 2,3-diaminopropanol is used in the synthesis of high value-added compounds, such as hydroxymethylpiperazine, D-threo-l-phenyl-2- decanoylamino-3 -morpholino- 1 -propanol, etc.
The object of the present invention is to provide a process for producing 2,3- diaminopropanol derivatives of formula (2) which act as intermediates in the synthesis of medicaments from aziridine alcohol of formula (1) and a process for producing the other useful compounds therefrom. Accordingly, the processes of the present invention can have four preparations as follows.
Preparation 1
A compound of formula (1) was reacted with halotrialkylsilane [Si(R)3X] to carry out a regiospecific ring opening reaction of the aziridine, and then the resulting intermediate was reacted with an amine (NHR3R4) to produce a compound of formula (2). This can be schematically illustrated in the following Scheme 1
Scheme 1
Figure imgf000003_0001
(1 ) (2) wherein R1 is selected from the group consisting of hydrogen; alkyl; cycloalkyl; 3- triazinyl or pyrimidyl acyl; aryl; hydrocarbon residues; aralkyl; and those substituted with suitable substituent(s), and includes 4-chlorophenyl, 4-methoxyphenyl, benzyl, 2,4- dimethoxyphenyl, (lR)-phenylethyl and (lS)-phenylethyl, preferences are given to (1R)- phenylethyl and (lS)-phenylethyl; R2 is selected from the group consisting of hydrogen; alkyl including, but not limiting to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, dodecyl; cycloalkyl including, but not limiting to cyclohexyl, cyclopentyl; C2-C5 alkenyl including, but not limiting to ethenyl, propenyl, butenyl, pentenyl; aralkyl; heteroaryl; and those which can be substituted with suitable substituent(s), preferences are given to hydrogen, lower alkyl, C2-C6 alkenyl, thiazolyl, phenyl, lower alkyl, lower alkoxy, or phenyl substituted halogen atom(s); and each R3 and R4 is independently selected from the group consisting of hydrogen, Cr C12 alkyl, C Cu alkylcarbonyl, CrC12 alkyloxycarbonyl, aryl, amino, mono- or di(C1-C12)alkyl amino, mono- or di(Cι-C12)aminocarbonyl, wherein CrCn may be optionally substituted with the suitable substituent(s), or R3 and R4, together with nitrogen atom which they are attached to, can form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C,- C12)alkylamino(C1-C4)alkylidene; with the proviso that Preparation 1 is excluded when R3 and R4 are both equal to hydrogen. Where R3 and R4 are both hydrogen, Preparation 2 may be applied. In this specification, the term "aryl" includes, but is not limited to, C5-C14 aromatic hydrocarbon group such as phenyl, indenyl, naphthyl, phenanthrenyl, anthracenyl etc.
The term "heteroaryl" includes, but is not limited to, 1 to 4 unsaturated 3- to 8- membered heterocyclic moieties containing 1 to 4 nitrogen atoms (e.g., pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl etc.); saturated 3- to 8-membered heterocyclic moieties containing 1 to 4 nitrogen atom(s) (e.g., pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl etc.); unsaturated condensed heterocyclic moieties containing 1 to 4 nitrogen atom(s) (e.g., indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl etc.); unsaturated 3- to 8-membered heterocyclic moieties containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) (e.g., oxazolyl, isoxazolyl, oxadiazolyl etc.); saturated 3- to 8-membered heterocyclic moieties containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) (e.g., morpholinyl etc.); unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) (e.g., benzoxazolyl, benzoxadiazolyl); unsaturated 3- to 8-membered heterocyclic moieties containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) (e.g., thiazolyl, isothiazolyl, thiadiazolyl, dihydrothiazinyl etc.); saturated 3- to 8-membered heterocyclic moieties containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) (e.g., thiazolinyl etc.); unsaturated 3- to 8-membered heterocyclic moieties containing 1 or 2 sulfur atom(s) (e.g., thienyl, dihydrodithiinyl, dihydrodithionyl etc.); saturated 3- to 8-membered heterocyclic moieties containing 1 or 2 oxygen atom(s) (e.g., tetrahydrofuryl, tetrahydropyranyl etc.); unsaturated condensed heterocyclic groups containing 1 or 2 sulfur atom(s) and 1 to 3 nitrogen atom(s) (e.g., benzothiazolyl, benzothiadiazolyl etc.); unsaturated 3- to 8-membered heterocyclic moieties containing 1 oxygen atom (e.g., furyl etc.); spiro heterocyclic moieties containing 1 or 2 oxygen atom(s) (e.g., dioxaspiroundecanyl etc.); unsaturated 3- to 8-membered heterocyclic moieties containing 1 oxygen atom and 1 or 2 sulfur atom(s) (e.g., dihydrooxathiinyl etc.); unsaturated condensed heterocyclic groups containing 1 or 2 sulfur atom(s) (e.g., benzothienyl, benzodithiinyl etc.); unsaturated condensed heterocyclic groups containing 1 oxygen atom and 1 or 2 sulfur atom(s) (e.g., benzoxathiinyl etc.). Preferences are given to pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 -oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, morpholinyl.
The term "suitable substituent(s)" includes, but is not limited to, lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl etc.), lower alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, isobutoxy, tert-butoxy, pentyloxy, neopentyloxy, tert-pentyloxy, hexyloxy etc.), lower alkenyl (e.g., vinyl, 1-propenyl, allyl, 1-methylallyl, 1-, 2- or 3-butenyI, 1-, 2-, 3- or 4-pentenyl etc.), lower alkynyl (e.g., ethynyl, 1-propynyl, propargyl, 1-methylpropargyl, 1-butynyl, 5-hexynyl etc.), mono- (or di- or tri-)halo(lower)alkyl (e.g., fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dibromomethyl, 2,2-difluoroethyl etc.), halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), carboxy, protected carboxy, hydroxy, protected hydroxy, aryl (e.g., phenyl, naphthyl etc.), ar(lower)alkyl, carboxy(lower)alkyl, protected carboxy(lower)alkyl, nitro, amino, protected imino, di(lower)alkylamino (e.g., dimethylamino, diethylamino, diisopropylamino etc.), hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, acyl, cyano, mercapto, lower alkylthio, imino. The term "aralkyl" includes, but is not limited to, phenyl(lower)alkyl such as benzyl, phenethyl, phenylpropyl.
The term "haIotrialkylsilane[Si(R)3X]" includes, but is not limited to, chlorotrimethylsilane, bromotrimethylsilane, iodotriethylsilane. The term "lower" means that the number of carbon is 1 to 6. The term "lower alkyl" indicates, but not limited to C,-C6 linear or branched moiety(ies) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, neopentyl, t-pentyl, hexyl, 1,1-dimethylbutyl, 2,2- dimethylbutyl, and the term "alkyl" includes, but is not limited to, linear or branched C,-C20 alkyl such as methyl, ethyl, propyl, 2-ethylhexyl, octyl, dodecyl, hexadecyl, and octadecyl. Also, all the preparation processes of the present invention are usually carried out in a solvent such as acetonitrile, benzene, N,N-dimethylformamide, tetrahydrofuran, methylene chloride, ethylene chloride, chloroform, diethyl ether or other solvents which do not adversely influence the reaction. Preferably, a conventional organic solvent can be used. More preferably halogenated organic solvent, and most preferably methylene chloride can be used. The reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
Preparation 2
An azidoaminoalcohol of formula (3) was produced by reacting a compound of formula (1), the same starting material as in Preparation 1 by a known process (Y. Lim, Tetrahedron Letters, 1995, 36, 8431, and B. C. Kim, Tetrahedron, 1996, 52, 12117), reacting the compound with azidotrialkylsilane[Si(R')3N3] to carry out a regiospecific ring opening reaction of the aziridine. 2,3-diaminopropanol of formula (4) was produced by reducing the obtained compound of formula (3) using a conventional azido reduction process. According to this procedure, a product wherein R3 and R4 are both hydrogen [i.e., a compound of formula (4)] can be produced.
Scheme 2 Si(R')3N3 reduction
Figure imgf000007_0002
Figure imgf000007_0001
Figure imgf000007_0003
(3) (4)
(1 )
"Azidotrialkylsilane[Si(R')3N3]M as used herein includes, but is not limited to, azidotrimethylsilane or azidotriethylsilane. Preference is given to azidotrimethylsilane. The "reduction" according to this invention can be commonly carried out by the conventional procedures in the art such as chemical reduction and catalytic reduction. The following is a brief introduction of the reduction procedure, which can be used in the present invention.
Suitable reducing agents to be used in the chemical reduction are hydride (e.g., lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride etc.); mixture of borane and tetrahydrofuran or di(lower)alkyl sulfide (e.g., dimethyl sulfide etc.); or mixture of metal (e.g., tin, zinc, iron etc.) or acid compound (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid etc.).
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalyst (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire etc.), palladium catalyst (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate etc.), nickel catalyst (e.g., reduced nickel, nickel oxide, Raney nickel etc.), cobalt catalyst (e.g., reduced cobalt, Raney cobalt etc.), iron catalyst (e.g., reduced iron, Raney iron, Ullmann iron etc.) and the like.
The known reduction procedures can be utilized in reducing an azido group to an amino group in Preparation 2, and the typical examples are reduction by LiAlH4, reduction by Ph3P and catalytic reduction (catalytic hydrogenation), etc.
The reduction is usually carried out in a solvent such as water, alcohol, tetrahydrofuran, dioxane, N,N-dimethylformamide, or a mixture thereof; or other solvents which do not adversely influence the reaction. When the acid used in chemical reduction is liquid, it can also act as a solvent.
The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
Preparation 3
A compound of formula (6) can be produced by subjecting 2,3-diaminopropanol of formula (5) (i.e., the compound of formula (2) obtained from Preparation 1, wherein R3 is hydrogen) to reduction as shown in Scheme 3, preferably reduction using a compound having a dialdehyde group and a hydride reducing agent. The compound of formula (6) was subjected to a conventional reduction in the presence of a compound capable of producing an amino protecting group (i.e., amino protector), preferably reduction by catalytic hydrogenation (catalytic reduction) as described above to produce a compound of formula (7). Typical compound of formula (7) includes l,4-di-t-Boc-2(R)-hydroxymethylpiperazine (wherein "Boc" stands for tert-butyloxycarbonyl).
Scheme 3
Figure imgf000008_0001
(5) (6) {')
wherein R1, R2 and R4 are as defined hereinbefore, and R5 is an amino protecting group, which is suitable for protecting (or blocking) an amino group from chemical reaction, and is easily removable after completing the desired reaction on the other site.
Typical examples of this type include substituted or unsubstituted acyl, aryl, aralkoxymethyl or aralkyl group etc. The name or size of amino protecting groups is not critical because they are removed after completing the desired reaction. However, those having 1 to 20 carbon atom(s), particularly 1 to 8 carbon atom(s) can be preferably used.
The term "acyl group" as used herein can have the broadest meaning in regard to this process. It includes an acyl group derived from aliphatic, aromatic aliphatic, aromatic or heterocyclic carboxylic acid or sulfonic acid as well as alkoxycarbonyl, aryloxycarbonyl, particularly aralkoxycarbonyl group. The examples of acyl group include, but are not limited to, alkanoyl such as acetyl, propionyl, butyryl, decanoyl etc.; aralkanoyl such as phenylacetyl etc.; aroyl such as benzoyl or toluyl etc.; aryloxyalkanoyl; alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, Boc, 2-iodoethoxycarbonyl etc.; aralkylcarbonyl such as Cbz(carbobenzoxy), 4-methoxybenzyloxycarbonyl, Fmoc (9- fluorenylmethoxycarbonyl) etc.; arylsulfonyl. As the amino protecting group, the preference is given to Boc, and also to Cbz, Fmoc, benzyl or acetyl. Thus, as the "amino protector" in the present invention, t-butyl carbonate, methylcarbamate, ethylcarbamate or 9- fluorenylmethylcarbamate can be preferably used.
The "hydride" includes, but is not limited to, lithium aluminum hydride, sodium borohydride or sodium cyanoborohydride.
The "a compound having a dialdehyde group" is well known in the art, and preferably glyoxal can be used.
Preparation 4
As can be seen in Scheme 4, the compound of formula (8) can be prepared by subjecting R1 group of the compound of formula (2) to a conventional reduction procedure, preferably to a reduction using catalytic hydrogenation as described hereinbefore, and then reacting it with alkanoyl halide (R6X). Typical examples of the compound of formula (8) include D-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol.
Scheme 4
Figure imgf000009_0001
(2) (8)
Unless otherwise indicated, R1, R2, R3 and R4 and the redction are as defined hereinbefore,
R6 includes, but is not limited to, alkanoyl group such as acetyl, propionyl, butyryl, valeryl, pivaloyl, hexanoyl, isobutyryl, 2-ethylbutyryl, 3,3-dimethylbutyryl, decanoyl, preference is given to decanoyl, and X is fluoro, chloro, bromo or iodo.
The following examples are given for the purpose of illustrating the present invention in more detail.
Example
Example 1
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-methylpropanol
N-[(S)-l-phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol (201 mg) was dissolved in methylene chloride, to which azidotrimethylsilane (0.25 ml) was added. The reaction mixture was stirred at ambient temperature for 12 hours, was treated with IN of aqueous hydrochloric acid solution and then was stirred for 1 more hour. The solution was neutralized with sodium hydrogen carbonate, and the reaction product was extracted twice each with 5.0 mi of methylene chloride. The combined organic extracts were dried under anhydrous magnesium sulfate, and the solution was filtered, concentrated in vacuo and purified to give 154 mg of product as an oil. Rf 0.21 (EtOAc/hexane 20:80). [α ]D 26= -146.3 (c 2.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.38-7.25 (m, 5H), 3.96 (q, J= 6.5 Hz, 1H), 3.64 (m, 2H), 3.35 (dd, J= 12.8, 3.0 Hz, 1H), 2.25 (m, 1H), 1.40 (d, J= 6.4 Hz, 3H), 1.09 (d, J= 6.2 Hz, 3H).
Example 2
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-n-butylpropanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l (R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)- [l(R)-n-butyl]methanol, the titled compound was produced. Rf 0.24 (EtOAc/hexane 20:80). [α ]D 27 = -98.6 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.33-7.24 (m, 5H), 3.95 (q, J- 6.5 Hz, IH), 3.63 (dd, J= 12.6, 4.6 Hz, IH), 3.39 (m, 2H), 2.33 (m, 2H), 1.38 (d, J= 6.5 Hz, 3H), 1.23 (m, 5H), 0.86 (m, 3H).
Example 3
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-t-butylpropanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l (R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)- [l(R)-t-butyl]methanol, the titled compound was produced.
Rf 0.46 (EtOAc/hexane 20:80). [α ]D 26= -99.2 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.33-7.24 (m, 5H), 3.97 (q, J= 6.6 Hz, IH), 3.64 (dd, J= 12.6, 4.6 Hz, IH), 3.32 (dd, J = 12.6, 4.8 Hz, IH), 2.98 (d, J- 4.9 Hz, IH), 2.77 (m, 2H), 2.62 (q, J = 4.8 Hz, IH), 1.42 (d, J= 6.5 Hz, 3H), 0.70 (s, 9H).
Example 4
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-phenylpropanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l (R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)- [1 (R)-phenyl]methanol, the titled compound was produced.
Rf 0.24 (EtOAc/hexane 20:80). [α ]D 2S= -134.2 (c 0.50, CHC13). Η NMR (200 MHz, CDC13) δ 7.38-7.17 (m, 10H), 4.43 (d, J= 8.5 Hz, IH), 3.52 (dd, J= 12.8, 4.0 Hz, IH), 3.02 (dd, J= 12.8, 2.9 Hz, IH), 2.56 (m, IH), 1.41 (d, J= 6.5 Hz, 3H).
Example 5
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(2-methoxy phenyl)propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)- [l(R)-(2-methoxyphenyl)]methanol, the titled compound was produced.
Rf 0.12 (EtOAc/hexane 20:80). [α ]D 26= -141.0 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.30-7.17 (m, 7H), 6.94-6.78 (m, 2H), 4.83 (d, J= 7.4 Hz, IH), 3.83 (q, J = 7.4 Hz, IH), 3.83 (q, J= 6.4 Hz, IH), 3.69 (s, 3H), 3.51 (dd, J- 12.6, 4.6 Hz, IH), 3.07 (dd, J = 12.8, 3.5 Hz, IH), 2.72 (m, IH), 1.37 (d, J= 6.6 Hz, 3H).
Example 6 Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(4-chlorophenyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l (R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)- [l(R)(4-chlorophenyl)]methanol, the titled compound was produced.
Rf 0.26 (EtOAc/hexane 20:80). [α ]D 26= -114.6 (c 1.00, CHC13). 'H NMR (200 MHz, CDC13) δ 7.38-7.11 (m, 9H), 4.42 (d, J = 8.3 Hz, IH), 3.92 (q, J = 6.5 Hz, IH), 3.57 (dd, J- 12.9, 4.1 Hz, IH), 3.04 (dd, J- 12.8, 2.8 Hz, IH), 1.42 (d, J- 6.5 Hz, 3H).
Example 7
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(l-hexynyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol with N-[(lS)-phenylethyl]aziridine-2(R)- [l(R)-(l-hexynyl)]methanol, the titled compound was produced.
Rf 0.28 (EtOAc/hexane 20:80). [α ]D 2 - -88.0 (c 1.00, CHC13). Η NMR (200
MHz, CDC13) δ 7.35-7.23 (m, 5H), 4.22 (m, IH), 3.96 (q, = 6.4 Hz, IH), 3.65 (dd, J= 12.6,
4.4 Hz, IH), 3.52 (dd, J= 12.5, 3.5 Hz, IH), 2.60 (m, IH), 2.18 (m, 2H), 1.39 (m, 7H), 0.88 (t,
J- 7.0 Hz, 3H). Example 8
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(4-fluorophenyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol with N-[(lS)-phenylethyl]aziridine-2(R)- [l(R)-(4-fluorophenyl)]methanol, the titled compound was produced.
Rf 0.22 (EtOAc/hexane 20:80). [α ]D 28= -136.0 (c 0.50, CHC13). Η NMR (200 MHz, CDC13) δ 7.38-6.92 (m, 9H), 4.42 (d, J = 8.4 Hz, IH), 3.93 (q, J = 6.3 Hz, IH), 3.57 (dd, J= 13.0, 3.8 Hz, IH), 3.01 (dd, J- 12.8, 2.4 Hz, IH), 2.48 (m, IH), 1.42 (d, J- 6.2 Hz, 3H).
Example 9
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(3-methylphenyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl] aziridine-2(R)- [ 1 (R)-methyl]methanol with N- [( 1 S)-phenylethyl]aziridine-2(R)- [l(R)-(3-methylphenyl)]methanol, the titled compound was produced.
Rf 0.29 (EtOAc/hexane 20:80). [α ]D 27= -128.0 (c 1.00, CHC13). !H NMR (200
MHz, CDC13) δ 7.37-6.99 (m, 9H), 4.40 (d, J - 8.4 Hz, IH), 3.91 (q, J = 6.5 Hz, IH), 3.54 (dd, J- 12.8, 4.0 Hz, IH), 3.03 (dd, J= 12.8, 2.7 Hz, IH), 2.54 (m, IH), 2.28 (s, 3H), 1.40 (d, J= 6.5 Hz, 3H).
Example 10
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(2-thiazolyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l (R)-methyl]methanol with N-[(l S)-phenylethyl]aziridine-2(R)-
[l(R)-(2-thiazolyl)]methanol, the titled compound was produced. mp 68-70 °C . Rf 0.27 (EtOAc/hexane 30:70). [α ]D 26= -81.2 (c 0.50, CHC13). Η NMR (200 MHz, CDC13) δ 7.68 (d, J= 3.3 Hz, IH), 7.32-7.16 (m, 6H), 4.79 (d, J= 6.4 Hz, IH), 3.83 (q, J= 6.6 Hz, IH), 3.68 (dd, J= 12.6, 4.7 Hz, IH), 3.59 (dd, J= 12.6, 4.3 Hz, IH), 2.85 (m, IH), 1.38 (d, J= 6.5 Hz, 3H).
Example 11
Synthesis of 2(R)-N-[(lS)-phenylethyl]amino-3-azido-l(R)-(2-propenyl) propanol
Using the analogous procedure described in Example 1, and replacing N-[(1S)- phenylethyl]aziridine-2(R)-[l(R)-methyl]methanol with N-[(lS)-phenylethyl]aziridine-2(R)- [l(R)-(2-propenyl)]methanol, the titled compound was produced.
Rf 0.38 (EtOAc/hexane 30:70). [α ]D 26= -158.2 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.38-7.25 (m, 5H), 4.96 (d, J - 13.9 Hz, 2H), 3.92 (m, 2H), 3.60 (dd, J = 12.5, 4.5 Hz, IH), 3.30 (dd, J= 12.5, 3.2 Hz, IH), 1.45 (s, 3H), 1.40 (d, J= 6.5 Hz, 3H).
Example 12
Synthesis of 2(R)-N-[(S)-l-phenylethyl]amino-3-pyrrolidinopropanol
N-[(S)-l-phenylethyl]aziridine-2(R)-methanol (60 mg) was dissolved in 1.0 ml of acetonitrile, and then 107 mg of sodium iodide and 86 mg of chlorotnmethylsilane were added to this solution. After stirring the reaction mixture at ambient temperature for 1 hour and 50 minutes, 16.8 mg of pyrrolidine was added, and then the reaction mixture was heated for 2 hours with stirring. After the reaction was completed, the reaction mixture was treated with 1.2N aqueous hydrochloric acid solution, neutralized with sodium hydrogen carbonate and extracted twice each with 5 mi of methylene chloride. The combined organic extracts were rinsed with brine, and dried under anhydrous magnesium sulfate. The solution was filtered, concentrated in vacuo, and purified to give 73 mg of titled product as an oil.
Rf 0.26 (MeOH/EtOAc 30:70). [α ]D 26= -19.4 (c 1.00, CHC13). Η NMR (500 MHz, CDC13) δ 7.10-7.36 (m, 10H), 4.80 (d, J = 3.9 Hz, IH), 3.76-3.80 (q, IH), 2.87 (m, IH), 2.61-2.72 (m, 6H), 1.79-1.81 (m, 4H), 1.24-1.25 (d, J= 6.35 Hz, 3H).
Example 13 Synthesis of 2(R)-N-[(S)-l-phenylethyl]amino-3-piperidinopropanol
Using the analogous procedure described in Example 12, and replacing pyrrolidine with piperidine, the titled compound was produced.
Rf 0.21 (MeOH/EtOAc 10:90). [α ]D 26= -35.5 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.14-7.33 (m, 10H), 4.74-1.80 (d, J= 4.0 Hz, IH), 3.71-3.81 (q, IH), 2.92- 3.00 (m, IH), 2.39-2.47 (m, IH), 1.44-1.80 (m, 6H), 1.21-1.24 (d, J= 6.6 Hz).
Example 14
Synthesis of 2(R)-N-[(S)-l-phenylethyl]amino-3-hexamethyleneimino propanol Using the analogous procedure described in Example 12, and replacing pyrrolidine with hexamethyleneimine, the titled compound was produced.
Rf 0.67 (MeOH/EtOAc 10:90). [α ]D 26= -33.7 (c 1.00, CHC13). Η NMR (200 MHz, CDC13) δ 7.17-7.33 (m, 10H), 4.70 (d, IH), 2.83-3.00 (m, IH), 2.55-2.83 (m, 7H), 1.55-1.94 (b, 8H), 1.21-1.24 (d, J= 6.6 Hz, 3H).
Example 15
Synthesis of 2(R)-N-[(S)-l-phenylethyI]amino-3-morpholino-l(R)-phenyl propanol Using the analogous procedure described in Example 12, and replacing pyrrolidine with morpholine, the titled compound was produced.
Rf 0.33 (EtOAc). [α ]D 26=-32.2 (c 1.00, CHC13). Η NMR (300 MHz, CDC13) δ 7.08-7.33 (m, 10H), 4.66 (d, J= 4.1 Hz, IH), 3.68-3.73 (m, 5H), 2.40-2.59 (m, 6H), 1.20 (d, J- 6.9 Hz, 3H).
Example 16
Synthesis of D-threo-l-phenyI-2-decanoylamino-3-morpholino-l-propanol 230 mg of 2(R)-N-[(S)-l-phenylethyl]amino-3-morpholino-l(R)-phenylpropanol obtained from Example 14 was dissolved in 3.4 mi of methanol, and 0.8 mi of acetic acid and 69 mg of Pd(OH)2 (25 wt%) were added to this solution. After thoroughly stirring the mixture, it was allowed to react under the atmospheric pressure and at 40 °C for 4 hours. The catalyst was filtered off, the reaction solution was concentrated in vacuo, and the residue was dissolved in 3 mi of tetrahydrofuran. 0.8 mi of 10% NaOH solution, followed by 0.13 mi of decanoyl chloride were added to this solution. After the completion of the reaction was confirmed by TLC, water was added to the reaction container. The solution was separated into an organic phase and an aqueous phase. The organic phase was dried under anhydrous magnesium sulfate. The solution was filtered, concentrated in vacuo and purified to give 212 mg of product as an oil.
Rf 0.40 (EtOAc). [α ]D 25 = +8.02 (c 0.30, CHC13). Η NMR (500 MHz, CDC13) δ 7.31 (m, 5H), 5.84 (d, J= 6.83 HZ, IH), 4.96 (d, J- 3.90 Hz, IH), 4.28 (m, IH), 3.72 (t, J = 4.88, 4.39 Hz, 4H), 2.47-2.62 (m, 6H), 2.10 (t, J= 7.32, 7.81 Hz, 2H), 1.50 (m, 2H), 1.23- 1.31 (m, 12H), 0.88 (t, J- 6.83 Hz, 3H).
The present invention produces the known 2,3-diaminopropanol in high yields of more than 90% by ring opening an inactivated optically pure aziridine and reacting with various amines. The obtained 2,3-diaminopropanol can be used in synthesis of high value-added fine chemical compounds, such as hydroxymethylpiperazine, D-threo-l-phenyl-2-decanoylamino- 3 -morpholino-1 -propanol etc.

Claims

Claims:
1. A process for producing 2,3-diaminopropanol, comprising the steps of:
(a) reacting an aziridine alcohol of formula (1) with halotrialkylsilane to carry out an regioselective ring opening reaction of aziridine, and
(b) immediately reacting the intermediate obtained from step (a) with amine
(NHR3R4) to produce 2,3-diaminopropanol of formula (2):
Figure imgf000017_0001
(1 ) (2)
wherein, R1 is selected from the group consisting of hydrogen; alkyl; cycloalkyl; 3- triazinyl or pyrimidyl acyl; aryl; hydrocarbon residues; aralkyl; and those groups substituted with suitable substituent(s);
R2 is selected from the group consisting of hydrogen; alkyl including methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl or dodecyl; cycloalkyl including cyclohexyl or cyclopentyl; C2-C5 alkenyl including ethenyl, propenyl, butenyl or pentenyl; aralkyl; heteroaryl; and those groups substituted with suitable substituent(s); each of R3 and R4 is independently selected from the group consisting of hydrogen, C,-C12 alkyl, CrC12 alkylcarbonyl, CrC12 alkyloxycarbonyl, aryl, mono- or di(C,- C12)alkylamino, mono- or di(Cι-C,2)aminocarbonyl, wherein C,-C12 may be optionally substituted with the suitable substituent(s), or R3 and R4, together with nitrogen atom which they are attached to, may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-C12)alkylamino(C1-C4)alkylidene; with the proviso that when R3 and R4 are not both equal to hydrogen.
2. The process according to Claim 1, wherein R2 is hydrogen, lower alkyl, lower alkenyl, thiazolyl, phenyl, or phenyl which may be optionally substituted with substituent(s) selected from a group consisting of lower alkyl, lower alkoxy and halogen atom.
3. The process according to Claim 1 or 2, wherein R1 is (lR)-phenylethyl or (1S)- phenylethyl.
4. The process according to Claim 1 or 2, wherein said halotrialkylsilane is selected from a group consisting of iodotrimethylsilane, chlorotrimethylsilane and bromotriethylsilane.
5. A process for producing 2,3-diaminopropanol, comprising the steps of:
(a) reacting an aziridine alcohol of formula (1) with azidotrialkylsilane to carry out a regioselective ring opening reaction of aziridine to produce azidoaminoalcohol of formula (3), and
(b) reducing the compound of formula (3) to produce 2,3-diaminopropanol of formula
(4):
Figure imgf000018_0001
(1) (3) (4) wherein R1 and R2 are as defined in Claim 1.
6. The process according to Claim 5, wherein the reduction is selected from a group consisting of a reduction with LiAlH4, a reduction with Ph3P and a catalytic hydrogenation.
7. The process according to Claims 5 or 6, wherein the azidotrialkylsilane is azidotrimethylsilane .
8. A process for producing a compound of formula (7), comprising the steps of:
(a) reducing 2,3-diaminopropanol of formula (5) which corresponds to a formula (2) wherein R3 is hydrogen to produce a compound of formula (6); and (b) reducing the compound of formula (6) in the presence of a amino protector to produce the compound of formula (7):
Figure imgf000018_0002
(5) (6) (7) wherein Rs is an amino protecting group, and R1, R2 and R4 are as defined in Claim 1.
9. The process according to Claim 8, wherein the reducing step (a) is carried out using a compound having a dialdehyde group and a hydride reducing agent, and the reducing step (b) is carried out by a catalytic hydrogenation.
10. The process according to Claim 9, wherein the compound having a dialdehyde group is glyoxal.
11. The process according to Claims 8 or 9, wherein said amino protector is selected from a group consisting of t-butyl carbonate, methylcarbamate, ethylcarbamate or 9- fluoreny lmethylcarbamate .
12. The process according to Claims 8 or 9, wherein R4 is benzyl.
13. A process for producing a compound of formula (8), comprising the steps of: (a) reducing R1 group of a compound of formula (2); and
(b) reacting the resulting product from step (a) with alkanoyl halide(R6X) to produce the compound of formula (8):
Figure imgf000019_0001
(2) (8) wherein R1, R2, R3 and R4 are as defined in Claim 1, R6 is an alkanoyl group, and X is fluoro, chloro, bromo or iodo.
14. The process according to Claim 13, wherein R3 and R4, together with nitrogen atom which they are attached to, form a morpholinyl group.
15. The process according to Claims 13 or 14, wherein the reduction is carried out by a catalytic hydrogenation.
16. The process according to Claims 13 or 14, wherein R6 is decanoyl.
PCT/KR2001/001362 2000-08-10 2001-08-10 Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols WO2002012185A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001277801A AU2001277801A1 (en) 2000-08-10 2001-08-10 Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2000/46394 2000-08-10
KR1020000046394A KR20000063913A (en) 2000-08-10 2000-08-10 Process for preparing 1,2-diaminopropane alcohols from aziridines

Publications (1)

Publication Number Publication Date
WO2002012185A1 true WO2002012185A1 (en) 2002-02-14

Family

ID=19682665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/001362 WO2002012185A1 (en) 2000-08-10 2001-08-10 Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols

Country Status (3)

Country Link
KR (2) KR20000063913A (en)
AU (1) AU2001277801A1 (en)
WO (1) WO2002012185A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000063913A (en) * 2000-08-10 2000-11-06 하현준 Process for preparing 1,2-diaminopropane alcohols from aziridines
EP2198864A1 (en) 2005-01-26 2010-06-23 Allergan, Inc. Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
CN103910655A (en) * 2014-04-11 2014-07-09 太原理工大学 Ring opening method of aziridine compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100420263B1 (en) * 2001-04-16 2004-03-02 한솔케미언스 주식회사 Process for preparing iso-serine and its derivatives from aziridine-2-carboxylates
KR101631481B1 (en) 2015-04-07 2016-06-17 고려대학교 산학협력단 Polymer using aziridine and method for preparing the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957823A (en) * 1972-04-15 1976-05-18 Badische Anilin- & Soda-Fabrik Aktiengesellschaft Electrophilic substitution of nitrosamines
US4040838A (en) * 1975-03-05 1977-08-09 Fuji Photo Film Co., Ltd. Processing color photographic materials
JPH01228946A (en) * 1988-03-09 1989-09-12 Suntory Ltd Synthesis of beta-hydroxyphenetylamines
EP0736509A2 (en) * 1995-04-07 1996-10-09 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56164129A (en) * 1980-05-20 1981-12-17 Takasago Corp Preparation of allyl alcohol
JPH0791239B2 (en) * 1988-11-22 1995-10-04 株式会社日本触媒 Method for producing ethylenediamine
US6063963A (en) * 1995-07-05 2000-05-16 Pharm-Eco Laboratories, Inc. Amino acid-derived diaminopropanols
KR20000063913A (en) * 2000-08-10 2000-11-06 하현준 Process for preparing 1,2-diaminopropane alcohols from aziridines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957823A (en) * 1972-04-15 1976-05-18 Badische Anilin- & Soda-Fabrik Aktiengesellschaft Electrophilic substitution of nitrosamines
US4040838A (en) * 1975-03-05 1977-08-09 Fuji Photo Film Co., Ltd. Processing color photographic materials
JPH01228946A (en) * 1988-03-09 1989-09-12 Suntory Ltd Synthesis of beta-hydroxyphenetylamines
EP0736509A2 (en) * 1995-04-07 1996-10-09 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000063913A (en) * 2000-08-10 2000-11-06 하현준 Process for preparing 1,2-diaminopropane alcohols from aziridines
US8513288B2 (en) 2005-01-26 2013-08-20 Allergan, Inc. 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US8013000B2 (en) 2005-01-26 2011-09-06 Allergan, Inc. 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity
US8153666B2 (en) 2005-01-26 2012-04-10 Allergan, Inc. Compounds having analgesic and/or immunostimulant activity
EP2489658A1 (en) 2005-01-26 2012-08-22 Allergan, Inc. 3-Heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US8288556B2 (en) 2005-01-26 2012-10-16 Allergan, Inc. 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity
EP2198864A1 (en) 2005-01-26 2010-06-23 Allergan, Inc. Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
US8835463B2 (en) 2005-01-26 2014-09-16 Allergan, Inc. Compounds having analgesic and/or immunostimulant activity
US8927589B2 (en) 2005-01-26 2015-01-06 Allergan, Inc. 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity
US9278943B2 (en) 2005-01-26 2016-03-08 Exonhit Therapeutics Sa Methods of using as analgesics 1-benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9399628B2 (en) 2005-01-26 2016-07-26 Allergan, Inc. 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US9828349B2 (en) 2005-01-26 2017-11-28 Exonhit Therapeutics Sa 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
CN103910655A (en) * 2014-04-11 2014-07-09 太原理工大学 Ring opening method of aziridine compounds

Also Published As

Publication number Publication date
AU2001277801A1 (en) 2002-02-18
KR20030029816A (en) 2003-04-16
KR20000063913A (en) 2000-11-06

Similar Documents

Publication Publication Date Title
US10550138B2 (en) Chiral spiro phosphorus-nirogen-sulphur tridentate ligand, preparation method and application thereof
US8962839B2 (en) Chiral spiro-pyridylamidophosphine ligand compound, synthesis method therefor and application thereof
US11434201B2 (en) Processes for preparing pyrrolidine compounds
US9718795B2 (en) 1,4-cyclohexylamine derivatives and processes for the preparation thereof
JP4915019B2 (en) Binaphthol derivative and optical resolution and conversion method
US7307091B2 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
US20180312476A1 (en) Method for preparing oxazolidinone intermediate
JP6852215B2 (en) Voglibose Impurity I Hydrochloride Preparation Method
JP2009501229A (en) Highly selective serotonin and norepinephrine double reuptake inhibitors and uses thereof
US20060167278A1 (en) Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives
WO2020212157A1 (en) A process for the preparation of enantiomerically pure norepinephrine
WO2002012185A1 (en) Process for preparing 2,3-diaminopropanols and synthesis of other compounds using 2,3-diaminopropanols
US20040242887A1 (en) Deuterated n-substituted and alpha-substituted diphenylalkoxy acetic acid amino alkyl esters and medicaments containing these compounds
CA2702605C (en) Unprotected amino aldehydes and applications for same
US20210340168A1 (en) OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS
CA3055504A1 (en) Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative
CN112939849B (en) (S, S) -2, 8-diazabicyclo [4.3.0] nonane intermediate and preparation method and application thereof
US20230374029A1 (en) Manufacture of compounds and compositions for inhibiting the activity of shp2
CN112679363A (en) Method for preparing pentazocine intermediate
JP5384353B2 (en) Method for synthesizing aryloxypropylamine and heteroaryloxypropylamine
EP3411355B1 (en) Process for the preparation of trans-4-amino-1-cyclohexanecarboxylic acid
US4045560A (en) 2-Morpholine containing methano or ethano anthracene compounds
NZ254309A (en) Alpha-[tert.-aminomethyl)-benzenemethanol derivatives for treating urinary incontinence
US20100168385A1 (en) Process for preparing enantiomerically enriched amino-alcohols
CN110981838B (en) 5-imine-tetrahydrofuryl methylamine derivative and preparation method and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1020037001904

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020037001904

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSANT TO RULE 69 (EPO FORM 1205A) OF 20-06-03

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWR Wipo information: refused in national office

Ref document number: 1020037001904

Country of ref document: KR